---
title: "Barclays Remains a Buy on Ascendis Pharma (ASND)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292041343.md"
description: "Barclays analyst Eliana Merle maintained a Buy rating on Ascendis Pharma (ASND) with a $345 price target. Merle, a 4-star analyst in the Healthcare sector, has a 7.1% average return. The broader analyst consensus for ASND is a Strong Buy, with an average price target of $304.77."
datetime: "2026-07-08T08:47:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292041343.md)
  - [en](https://longbridge.com/en/news/292041343.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292041343.md)
---

# Barclays Remains a Buy on Ascendis Pharma (ASND)

Barclays analyst Eliana Merle maintained a Buy rating on Ascendis Pharma today and set a price target of $345.00.

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Merle is a 4-star analyst with an average return of 7.1% and a 52.26% success rate. Merle covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, PTC Therapeutics, and Alnylam Pharma.

Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $304.77.

### Related Stocks

- [ASND.US](https://longbridge.com/en/quote/ASND.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md)
- [PTCT.US](https://longbridge.com/en/quote/PTCT.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [Ascendis Pharma posts slide presentation on achondroplasia program updates](https://longbridge.com/en/news/295105171.md)
- [Bank of New York Mellon Corp Reduces Stock Position in Ascendis Pharma A/S $ASND](https://longbridge.com/en/news/293716720.md)
- [These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results](https://longbridge.com/en/news/295423642.md)
- [Marks Group Wealth Management Inc Purchases New Shares in Ascendis Pharma A/S $ASND](https://longbridge.com/en/news/293016157.md)
- [Tvardi Therapeutics (TVRD) Gets a Sell from Barclays](https://longbridge.com/en/news/295203580.md)